News
VOR
0.8673
-2.19%
-0.0194
Weekly Report: what happened at VOR last week (1209-1213)?
Weekly Report · 6d ago
Vor Biopharma Price Target Maintained With a $17.50/Share by HC Wainwright & Co.
Dow Jones · 12/10 17:21
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Benzinga · 12/10 17:11
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Dow Jones · 12/10 16:51
JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Benzinga · 12/10 16:41
Positive Outlook for Vor Biopharma’s Trem-cel in AML Trials Leads to Buy Rating
TipRanks · 12/10 14:16
Optimistic Buy Rating for Vor Biopharma Based on Promising Clinical Trial Developments and Strong Financial Position
TipRanks · 12/10 06:15
Vor Bio trem-cel relapse-rate remains low, says Oppenheimer
TipRanks · 12/09 20:25
Vor Biopharma’s Strategic Advances and Promising Clinical Trial Results Justify Buy Rating
TipRanks · 12/09 19:45
Vor Bio Reports Promising Clinical Data for Trem-cel + Mylotarg in Acute Myeloid Leukemia Patients Post-Transplant
Barchart · 12/09 16:50
Vor Bio announces updated data from Phase 1/2 VBP1-1 study
TipRanks · 12/09 13:51
Vor Biopharma Reports Promising Phase 1/2 Study Results
TipRanks · 12/09 13:11
Stifel Nicolaus Remains a Buy on Vor Biopharma (VOR)
TipRanks · 12/09 12:57
Vor Bio Presents Data on AML Therapy at ASH 2024 Annual Meeting
Benzinga · 12/09 12:33
VOR BIO PROVIDES CLINICAL UPDATE FURTHER VALIDATING APPROACH OF USING SHIELDED TRANSPLANTS TO DELIVER TARGETED THERAPIES; RECEIVES SUPPORTIVE FEEDBACK FROM FDA REGARDING REGISTRATIONAL TRIAL DESIGN
Reuters · 12/09 12:30
Weekly Report: what happened at VOR last week (1202-1206)?
Weekly Report · 12/09 09:22
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
Barchart · 12/09 06:30
Weekly Report: what happened at VOR last week (1125-1129)?
Weekly Report · 12/02 09:22
Weekly Report: what happened at VOR last week (1118-1122)?
Weekly Report · 11/25 09:21
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
TipRanks · 11/25 06:00
More
Webull provides a variety of real-time VOR stock news. You can receive the latest news about Vor Biopharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VOR
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.